Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets blood cancer relapse

NCT ID NCT06547866

Not yet recruiting Disease control Sponsor: French Innovative Leukemia Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two oral drugs, zanubrutinib and BGB-11417, in adults with Waldenström macroglobulinemia who have already received at least one prior treatment. The goal is to see if the combination can shrink or control the cancer better than current options. Participants will take the drugs for about 20 months, and the study will monitor response rates and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

  • AMIENS - CH Amiens Picardie Site Sud

    Amiens, 80054, France

  • ANNECY - CH Annecy Genevois

    Annecy, 74374, France

  • APHP - Hôpital Pitié Salpêtrière - Hématologie

    Paris, 75651, France

  • ARGENTEUIL - Centre hospitalier Victor Dupouy

    Argenteuil, France

  • Angers Chu

    Angers, 49933, France

  • BAYONNE - CH de la Côte Basque - Hématologie

    Bayonne, 64109, France

  • BESANCON - Hôpital Jean Minjoz

    Besançon, 25000, France

  • Bordeaux Pessac

    Pessac, 33604, France

  • Bordeaux-Institut Bergonié

    Bordeaux, 33076, France

  • CAEN - CHU Caen - IHBN

    Caen, 14033, France

  • CRETEIL - CHU Henri Mondor

    Créteil, 94000, France

  • Clermont-Ferrand - Chu Estaing

    Clermont-Ferrand, 63000, France

  • DIJON - Hôpital François Mitterrand

    Dijon, 21000, France

  • Grenoble - CHUGA - Hématologie Clinique

    Grenoble, 38043, France

  • LILLE CHU - Hôpital Claude Huriez

    Lille, 59037, France

  • LILLE GHICL - Hôpital Saint Vincent de Paul

    Lille, 59000, France

  • LYON HCL - CH Lyon Sud

    Pierre-Bénite, 69036, France

  • LYON-Centre Léon Bérard

    Lyon, 69008, France

  • La Roche Sur Yon - Chd Vendee

    La Roche-sur-Yon, 85925, France

  • Le Mans CH

    Le Mans, France

  • MARSEILLE - Institut Paoli-Calmettes

    Marseille, 13000, France

  • MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique

    Montpellier, 34295, France

  • Mulhouse - Ghrmsa

    Mulhouse, 68100, France

  • NANCY - CHU Brabois

    Vandœuvre-lès-Nancy, 54500, France

  • NANTES - Hôpital Hôtel Dieu - Hématologie Clinique

    Nantes, 44093, France

  • ORLEANS - CHR - Hématologie

    Orléans, 44100, France

  • PERPIGNAN - CH St Jean - Hématologie Clinique

    Perpignan, 66000, France

  • POITIERS - Hématologie et Thérapie Cellulaire

    Poitiers, 86021, France

  • RENNES - CHU Pontchaillou - Hématologie Clinique

    Rennes, 35033, France

  • ROUEN - Centre Henri Becquerel - Service Hématologie Clinique

    Rouen, 76038, France

  • Reims Chu

    Reims, 51092, France

  • Strasbourg - Icans

    Strasbourg, 67033, France

  • TOURS - Hôpital Bretonneau

    Tours, 37000, France

  • Toulouse - IUCT Oncopole - Service d'Hématologie

    Toulouse, 31059, France

  • VERSAILLES - Hôpital André Mignot

    Versailles, France

  • Vannes - Chba

    Vannes, France

  • Villejuif Igr

    Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.